Schwartz TW - Search Results

1

Nonpeptide and peptide growth hormone secretagogues act both as ghrelin receptor agonist and as positive or negative allosteric modulators of ghrelin signaling.

Holst B, Brandt E, Bach A, Heding A, Schwartz TW. Holst B, et al. Among authors: schwartz tw. Mol Endocrinol. 2005 Sep;19(9):2400-11. doi: 10.1210/me.2005-0059. Epub 2005 May 19. Mol Endocrinol. 2005. PMID: 15905359

2

Non-peptide angiotensin agonist. Functional and molecular interaction with the AT1 receptor.

Perlman S, Schambye HT, Rivero RA, Greenlee WJ, Hjorth SA, Schwartz TW. Perlman S, et al. Among authors: schwartz tw. J Biol Chem. 1995 Jan 27;270(4):1493-6. doi: 10.1074/jbc.270.4.1493. J Biol Chem. 1995. PMID: 7829475 Free article.

3

Evidence for a common molecular mode of action for chemically distinct nonpeptide antagonists at the neurokinin-1 (substance P) receptor.

Gether U, Emonds-Alt X, Brelière JC, Fujii T, Hagiwara D, Pradier L, Garret C, Johansen TE, Schwartz TW. Gether U, et al. Among authors: schwartz tw. Mol Pharmacol. 1994 Mar;45(3):500-8. Mol Pharmacol. 1994. PMID: 8145735

4

Radioligand-dependent discrepancy in agonist affinities enhanced by mutations in the kappa-opioid receptor.

Hjorth SA, Thirstrup K, Schwartz TW. Hjorth SA, et al. Among authors: schwartz tw. Mol Pharmacol. 1996 Oct;50(4):977-84. Mol Pharmacol. 1996. PMID: 8863844

5

Dual agonistic and antagonistic property of nonpeptide angiotensin AT1 ligands: susceptibility to receptor mutations.

Perlman S, Costa-Neto CM, Miyakawa AA, Schambye HT, Hjorth SA, Paiva AC, Rivero RA, Greenlee WJ, Schwartz TW. Perlman S, et al. Among authors: schwartz tw. Mol Pharmacol. 1997 Feb;51(2):301-11. doi: 10.1124/mol.51.2.301. Mol Pharmacol. 1997. PMID: 9203636

6

Constitutive activity of glucagon receptor mutants.

Hjorth SA, Orskov C, Schwartz TW. Hjorth SA, et al. Among authors: schwartz tw. Mol Endocrinol. 1998 Jan;12(1):78-86. doi: 10.1210/mend.12.1.0045. Mol Endocrinol. 1998. PMID: 9440812

7

Steric hindrance mutagenesis versus alanine scan in mapping of ligand binding sites in the tachykinin NK1 receptor.

Holst B, Zoffmann S, Elling CE, Hjorth SA, Schwartz TW. Holst B, et al. Among authors: schwartz tw. Mol Pharmacol. 1998 Jan;53(1):166-75. doi: 10.1124/mol.53.1.166. Mol Pharmacol. 1998. PMID: 9443945

8

Natural agonist enhancing bis-His zinc-site in transmembrane segment V of the tachykinin NK3 receptor.

Rosenkilde MM, Lucibello M, Holst B, Schwartz TW. Rosenkilde MM, et al. Among authors: schwartz tw. FEBS Lett. 1998 Nov 13;439(1-2):35-40. doi: 10.1016/s0014-5793(98)01331-3. FEBS Lett. 1998. PMID: 9849872 Free article.

9

Conversion of agonist site to metal-ion chelator site in the beta(2)-adrenergic receptor.

Elling CE, Thirstrup K, Holst B, Schwartz TW. Elling CE, et al. Among authors: schwartz tw. Proc Natl Acad Sci U S A. 1999 Oct 26;96(22):12322-7. doi: 10.1073/pnas.96.22.12322. Proc Natl Acad Sci U S A. 1999. PMID: 10535920 Free PMC article.

10

Potency of ligands correlates with affinity measured against agonist and inverse agonists but not against neutral ligand in constitutively active chemokine receptor.

Rosenkilde MM, Schwartz TW. Rosenkilde MM, et al. Among authors: schwartz tw. Mol Pharmacol. 2000 Mar;57(3):602-9. doi: 10.1124/mol.57.3.602. Mol Pharmacol. 2000. PMID: 10692502

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

367 results

Search Page

Filters